Stock Fundamentals

Company Information

Company Name
Esperion Therapeutics Inc
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ
ISIN: US29664W1053
CIK: 0001434868
CUSIP: 29664W105
Currency: USD
Full Time Employees: 294
Phone: 734 887 3903
Fiscal Year End: December
IPO Date: Jun 26, 2013
Description:

Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was formerly known as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics, Inc. in May 2008. The company was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Address:

3891 Ranchero Drive, Ann Arbor, MI, United States, 48108

Directors & Officers

Name Title Year Born
Mr. Sheldon L. Koenig M.B.A. President, CEO & Director 1966
Mr. Benjamin Halladay M.B.A. Chief Financial Officer 1986
Mr. John B. Harlow Jr. Chief Commercial Officer 1976
Mr. Glenn P. Brame Chief Technical Operations Officer 1957
Mr. Benjamin O. Looker J.D. Chief Legal & Corporate Affairs Officer 1982
Tiffany Aldrich M.B.A. Associate Director of Corporate Communications NA
Ms. Betty Jean Swartz Chief Business Officer NA
LeAnne Bloedon M.S. VP & Head of Development NA
Dr. Stephen Pinkosky Vice President of Drug Discovery of Early Pre-Clinical Development NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Mar 17, 2026 Benjamin Halladay N/A Sale 6.42K $2.71 $17.41K
Mar 17, 2026 Benjamin Looker N/A Sale 5.71K $2.70 $15.41K
Jan 20, 2026 Benjamin Looker N/A Sale 1.69K $2.88 $4.86K
Dec 17, 2025 Benjamin Halladay N/A Sale 7.34K $3.67 $26.93K
Dec 17, 2025 Benjamin Looker N/A Sale 6.52K $3.67 $23.92K
Sep 17, 2025 Benjamin Halladay N/A Sale 7.05K $2.81 $19.80K
Sep 17, 2025 Benjamin Looker N/A Sale 6.27K $2.80 $17.55K
Jul 17, 2025 Benjamin Halladay N/A Sale 11.00 $1.11 $12.21
Jul 17, 2025 Benjamin Looker N/A Sale 1.30K $1.13 $1.47K
Jun 17, 2025 Benjamin Halladay N/A Sale 7.23K $1.15 $8.31K
Jun 17, 2025 Benjamin Looker N/A Sale 6.42K $1.15 $7.39K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BlackRock Inc 17.85M Mar 31, 2026 6.93% $0.00 0.96%
Wasatch Advisors LP 15.77M Mar 31, 2026 6.13% $0.29 66.94%
Vanguard Group Inc 14.95M Dec 31, 2025 5.81% $0.00 23.59%
Two Seas Capital LP 11.39M Mar 31, 2026 4.43% $0.44 -4.27%
Orbimed Advisors, LLC 10.57M Mar 31, 2026 4.11% $0.57 77.19%
Two Sigma Investments LLC 9.46M Mar 31, 2026 3.67% $0.02 99.46%
Marshall Wace Asset Management Ltd 7.08M Mar 31, 2026 2.75% $0.02 29.31%
State Street Corp 7.06M Mar 31, 2026 2.74% $0.00 18.98%
D. E. Shaw & Co LP 6.54M Mar 31, 2026 2.54% $0.01 -5.25%
Geode Capital Management, LLC 5.96M Mar 31, 2026 2.31% $0.00 3.80%
AIGH Capital Management, LLC 4.40M Mar 31, 2026 1.71% $1.64 10.00%
UBS Group AG 4.29M Mar 31, 2026 1.67% $0.00 1,269.61%
Armistice Capital, LLC 3.93M Mar 31, 2026 1.53% $0.19 0.00%
Penderfund Capital Management Ltd 3.89M Mar 31, 2026 1.51% $1.67 -11.38%
Nuveen, LLC 3.61M Mar 31, 2026 1.40% $0.00 0.04%
Two Sigma Advisers, LLC 3.51M Dec 31, 2025 1.36% $0.03 83.71%
Privium Fund Management B.V. 3.30M Mar 31, 2026 1.28% $1.88 0.00%
Morgan Stanley - Brokerage Accounts 2.74M Mar 31, 2026 1.06% $0.00 -22.16%
Royce & Associates, LP 2.63M Mar 31, 2026 1.02% $0.07 -27.06%
The Goldman Sachs Group Inc 2.41M Mar 31, 2026 0.94% $0.00 -15.37%

Shares Statistics

Shares Outstanding: 257.43M
Shares Float: 254.78M
% Insiders: 77.50%
% Institutions: 6,977.60%
Short % Float: 7.97%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 7.53M 2.92% ▲ 0.00% Apr 30, 2026
2 iShares Russell 2000 ETF 5.66M 2.20% ▲ 0.85% Apr 30, 2026
3 Wasatch Small Cap Growth Investor 3.81M 1.48% ▲ 0.00% Mar 31, 2026
4 Wasatch Ultra Growth 3.77M 1.46% ▼ 14.70% Mar 31, 2026
5 Biotech Growth Ord 3.74M 1.45% ▲ 0.00% Feb 28, 2026
6 Pender Corporate Bond A 3.56M 1.38% ▼ 12.32% Feb 28, 2026
7 Wasatch Micro Cap 3.03M 1.18% ▲ 7.56% Mar 31, 2026
8 Nuveen Quant Small Cap Equity R6 3.02M 1.17% ▲ 0.00% Mar 31, 2026
9 Vanguard Institutional Extnd Mkt Idx Tr 2.68M 1.04% ▲ 0.50% Apr 30, 2026
10 State Street® SPDR® S&P® PhrmctlsETF 2.37M 0.92% ▲ 0.00% Apr 30, 2026

Valuation Metrics

Enterprise Value: $903.52M
Trailing P/E: 0.00
Forward P/E: 4.64

Financial Highlights

Market Cap: $808.34M
EBITDA: $75.89M
P/E Ratio: $0.00
PEG Ratio: $-4.78
Book Value: $-1.23
Earnings/Share: $0.00
Profit Margin: -1.78%
Operating Margin: -8.22%
ROA (TTM): 12.04%
ROE (TTM): -260.79%
Revenue (TTM): $418.24M
Revenue/Share (TTM): $1.89
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 23.20%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 0.56x -1.12x 1.65x 0.71x 5.63x
2024-12-31 1.37x -0.88x 2.13x 0.92x 45.27x
2023-12-31 1.29x -0.65x 3.21x -2.64x -1.99x
2022-12-31 2.67x -0.80x 2.31x -3.16x -1.48x
2021-12-31 4.48x -1.32x 1.52x -4.89x -1.17x
2020-12-31 3.68x -1.89x 1.27x -5.35x -1.51x
2019-12-31 3.20x 6.40x 0.91x -11.47x -1.44x
2018-12-31 2.22x 0.00x 0.45x -2,045.85x 0.00x
2017-12-31 6.15x 0.00x 0.12x -853.44x -0.01x
2016-12-31 13.70x 0.01x 0.07x -202.53x -0.04x
2015-12-31 38.11x 0.01x 0.03x -96.23x -0.09x
2014-12-31 19.44x 0.04x 0.07x -134.16x -0.14x
2013-12-31 14.42x 0.00x 0.05x -24.30x 0.00x
2012-12-31 0.42x -1.16x 3.38x -6.86x -2.00x
2011-12-31 1.39x -0.83x 3.78x -17.61x -0.50x
2002-12-31 9.18x 0.03x 0.25x N/A -0.04x
2001-12-31 11.21x 0.01x 0.15x N/A -0.03x
2000-12-31 9.97x 0.01x 0.13x N/A -0.03x
1999-12-31 2.08x 0.18x 0.65x N/A -0.04x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about ESPR.US!